GENOMICS ENGLAND is partnering with GenomOncology LLC to use GenomOncology’s Knowledge Management System to analyze cancer samples in the 100,000 Genomes Project. This partnership will couple Genomics England curated database with the GO KMS’s clinical reporting data for a comprehensive clinical report comprised of the most relevant drugs, prognoses, and clinical trials. The GO KMS... […]
BOEHRINGER INGELHEIM and ViraTherapeutics announced a long-term collaboration to develop a next-generation oncolytic virus therapy platform and to investigate the ViraTherapeutics lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) alone and in combination with other therapies. ViraTherapeutics has developed its technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund and... […]
JANSSEN RESEARCH & DEVELOPMENT LLC said a supplemental New Drug Application for ibrutinib (Imbruvica) has been submitted to FDA for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy. The filing is based on data from the multi-center, open-label Phase II PCYC-1121 trial ((NCT01980628) assessing the use of ibrutinib, a BTK... […]
DIGNITY HEALTH and Catholic Health Initiatives announced the launch of the Precision Medicine Alliance LLC, which will offer patients from both health care systems faster and more accurate diagnostic and treatment protocols based on their genetic and molecular profile information.
THE ONCOLOGY RESEARCH INFORMATION EXCHANGE NETWORK (ORIEN) and HudsonAlpha Institute of Biotechnology announced a new collaboration to advance cancer research and care called The ORIEN Avatar Research Program. Under the agreement, HudsonAlpha will provide DNA sequences for 20,000 patient samples, tumor and non-tumor, by 2019 to identify the genetic disturbances and mutations of each patient’s... […]
ST. JUDE CHILDREN’S RESEARCH HOSPITAL and The Wellcome Trust Sanger Institute, UK, agreed to a full exchange of cancer mutation data to support the discovery and understanding of genetic mutations causing cancers. The agreement will provide regular updates and exchanges of data between both institutions to ensure the best support for research in all areas... […]
GOLDEN MEDITECH HOLDINGS LTD., a Hong Kong-based healthcare enterprise, and MD Anderson Cancer Center announced the creation of Cellenkos Inc., a start-up enterprise focused on umbilical cord blood derived T-regulatory cellular therapies. Cellenkos, to be based in Houston, is funded with an initial investment of $10 million with warrants to purchase an additional $10 million... […]
ELI LILLY & CO. said that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending the granting of a conditional marketing authorization for olaratumab, in combination with doxorubicin, for the treatment of adults in the European Union with advanced soft tissue sarcoma not amenable to curative treatment with... […]
FDA granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
AMGEN and Boehringer Ingelheim said Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager that targets B-cell maturation antigen, a potential target for multiple myeloma. BI 836908 (AMG 420) is currently in phase I studies. Under the agreement, Amgen will work with Boehringer... […]
